$529 Million is the total value of JOHNSON & JOHNSON's 22 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | $131,006,000 | -33.7% | 3,379,064 | 0.0% | 24.77% | +10.0% | |
| LEGN | Legend Biotech Corporationads | $59,204,000 | -22.0% | 1,629,173 | 0.0% | 11.19% | +29.5% | |
| PTGX | Protagonist Therapeutics Inc. | $57,997,000 | -30.8% | 2,449,183 | 0.0% | 10.96% | +15.0% | |
| ARWR | Sell | Arrowhead Pharmaceuticals, Inc. | $57,987,000 | -73.2% | 1,260,869 | -61.3% | 10.96% | -55.5% |
| MGTX | MeiraGTx Holdings plc | $40,145,000 | -41.7% | 2,898,550 | 0.0% | 7.59% | -3.1% | |
| Cue Health, Inc. | $35,790,000 | -51.9% | 5,548,864 | 0.0% | 6.77% | -20.1% | ||
| Procept BioRobotics Corporation | $35,637,000 | +39.9% | 1,018,478 | 0.0% | 6.74% | +132.3% | ||
| FUSN | Fusion Pharmaceuticals Inc. | $28,520,000 | +86.3% | 3,670,516 | 0.0% | 5.39% | +209.5% | |
| CVRX | CVRx, Inc. | $20,938,000 | -51.0% | 3,495,575 | 0.0% | 3.96% | -18.7% | |
| XNCR | Xencor, Inc. | $19,958,000 | -33.5% | 748,062 | 0.0% | 3.77% | +10.4% | |
| ACET | Adicet Bio, Inc. | $14,557,000 | +14.2% | 728,944 | 0.0% | 2.75% | +89.7% | |
| PNT | Point Biopharma Global Inc. | $7,970,000 | +42.3% | 1,000,000 | 0.0% | 1.51% | +136.2% | |
| VOR | Vor Biopharma, Inc. | $6,491,000 | -48.0% | 1,074,658 | 0.0% | 1.23% | -13.7% | |
| PHGE | BiomX Inc. | $4,117,000 | +20.6% | 2,133,402 | 0.0% | 0.78% | +100.0% | |
| SomaLogic, Inc. | $2,254,000 | -31.1% | 281,052 | 0.0% | 0.43% | +14.5% | ||
| PHAS | PhaseBio Pharmaceuticals, Inc. | $2,121,000 | -49.4% | 1,607,044 | 0.0% | 0.40% | -15.9% | |
| NNOX | Nano-X Imaging Ltd. | $2,086,000 | -25.4% | 192,429 | 0.0% | 0.39% | +23.5% | |
| ALDX | Aldeyra Therapeutics, Inc. | $1,755,000 | +11.1% | 394,834 | 0.0% | 0.33% | +84.4% | |
| TCON | Tracon Pharmaceuticals, Inc. | $221,000 | -5.2% | 84,003 | 0.0% | 0.04% | +55.6% | |
| SENS | Senseonics Holdings, Inc. | $108,000 | -26.0% | 54,621 | 0.0% | 0.02% | +17.6% | |
| GRAY | Graybug Vision, Inc. | $61,000 | -33.0% | 49,547 | 0.0% | 0.01% | +20.0% | |
| CBIO | Catalyst Biosciences, Inc. | $44,000 | -27.9% | 66,951 | 0.0% | 0.01% | +14.3% | |
| LUNG | Exit | Pulmonx Corporation | $0 | – | -5,639 | -100.0% | -0.02% | – |
| CSLT | Exit | Castlight Health, Inc. | $0 | – | -811,295 | -100.0% | -0.14% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.